Abivax S.A. (ABVX) stock profile

Frequently asked questions

What does Abivax S.A. (ABVX) do?

ABIVAX Société Anonyme discovers and develops drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its lead product candidate, ABX464, is in Phase IIb clinical trials for ulcerative colitis and Crohn's disease, as well as for COVID-19, and has completed a Phase IIa trial for viral remission in HIV patients. The company is also developing ABX196, an immune enhancer candidate in Phase 1/2 clinical trials for hepatocellular cancer. Additionally, ABIVAX conducts research programs for Dengue fever, influenza, and respiratory syncytial virus. The company has licensing agreements with the French National Centre for Scientific Research, the University of Montpellier, and Institut Curie. Founded in 2013, ABIVAX Société Anonyme is headquartered in Paris, France.

Where is ABVX stock listed?

Abivax S.A. trades under the ticker ABVX on NASDAQ.

How can I research ABVX's financials and filings?

Vantafin provides Abivax S.A.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the ABVX profile.